BriaCell Therapeutics Corp. BCTXF Archives - Page 5 of 6

MondayNov 19, 2018 10:25 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Continues Advancement of Clinical Program

Multiple important steps have contributed to the advancement of the BriaCell clinical program in 2018 The company has gotten excellent results from its Bria-IMT clinical trials and hopes to begin Bria-OTS testing in 2019 The personalized, off-the-shelf advanced breast cancer treatment will be much more cost-effective to manufacture than alternatives and is expected to produce fewer side effects Throughout 2018, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) has been working hard on the advancement of its clinical program. The company attained crucial safety and efficacy data via its clinical trials, and it also achieved proof of concept. The phase I/IIa…

ThursdayNov 15, 2018 1:09 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Developing a Personalized Advanced Breast Cancer Treatment

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, is currently developing a personalized immunotherapy drug to treat advanced breast cancer. A recent article further discussing the company reads, “Based on its research results, the company is developing a second immunotherapy drug, Bria-OTS, an off-the-shelf personalized treatment that’s expected to be effective for 90 percent of the advanced breast cancer patient population. Bria-OTS is expected to go to clinical trials in 2019. … BriaCell Therapeutics Corp., based in Berkeley, California, and headquartered in Vancouver, British Columbia, is an immuno-oncology focused biotechnology company developing targeted…

FridayNov 09, 2018 11:05 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) CEO Talks Key Aspects of Company’s Technology, Personalized Breast Cancer Treatment

BriaCell is on its way to developing a personalized, off-the-shelf immunotherapy for advanced breast cancer patients Because of the market gap and the demand for such treatments, the development and release of the product could be fast tracked BriaCell has obtained excellent results in clinical trials so far as Bria-IMT demonstrates the ability to shrink tumors at multiple sites in patients with advanced breast cancer BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is developing the first personalized, off-the-shelf advanced breast cancer immunotherapy option using its proprietary targeted immunotherapy technology, company president and CEO Dr. Bill Williams said in a recent…

TuesdayNov 06, 2018 11:51 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) CEO Discusses Personalized Immunotherapies in Interview on Uptick Newswire’s Stock Day Podcast

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT) an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, was recently featured on Uptick Newswire’s Stock Day Podcast. Dr. Bill Williams, BriaCell’s president and CEO, was interviewed for the podcast by Everett Jolly of Stock Day. Per the interview, Dr. Williams expressed his enthusiasm regarding the company’s future, as he believes BriaCell is on the cutting edge of cancer treatment with its effective and safe immunotherapy applications. Williams also detailed BriaCell’s current major programs: Bria-IMT, which is in the clinic right now, and Bria-OTS, which is in development. “BriaCell is developing the…

FridayNov 02, 2018 2:41 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Continues to Advance Promising BriaCell Clinical Program

During 2018, BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT) has attained topline safety and efficacy clinical data in a clinical trial, achieved proof of concept and advanced its BriaCell clinical program. A recent article further discussing the important milestones the company has reached reads, “BriaCell recently announced excellent safety and efficacy data from a phase I/IIa proof of concept clinical study in advanced breast cancer patients. There were reports of tumor shrinkage in various sites. These results were confirming the findings from two previous proof-of-concept clinical trials that showed promising results in patients with advanced breast cancer. The most notable result…

FridayNov 02, 2018 11:52 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Developing the First Personalized OTC Immunotherapy Drug for Advanced Breast Cancer

41,000 women in the U.S. are expected to die of breast cancer in 2018 BriaCell is developing a breast cancer drug that can be quickly prepared for individualized treatment Clinical trials demonstrate tumor shrinkage with no serious side effects BriaCell is now in clinical trials with its lead immunotherapy treatment, tested in combination with other already-approved cancer fighting drugs Immunotherapy drugs are expected to be a $100 billion business by 2021 Breast cancer is the second-leading cause of cancer death for U.S. women. Although death rates from this disease have been falling since 1989, still in 2018 nearly 41,000 Americans…

ThursdayOct 25, 2018 10:45 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Breast Cancer Therapy Trials to Patient Dosing Stage

Breast cancer is the leading cancer diagnosed in women and the second-most common cancer overall BriaCell Therapeutics has begun patient dosing in clinical trials that combine its trademarked Bria-IMT technology with celebrated cancer-fighting antibodies The clinical trials are working on a therapy that will help the body’s own immune system fight cancerous cells The battle against breast cancer is taking a technological turn amid an increasing drive to develop therapies that use the body’s own immune system to destroy life-threatening cancer cells. BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is on the front line of the battle and is currently…

MondayOct 22, 2018 1:15 pm

QualityStocksNewsBreaks – Patient Dosing Underway in BriaCell Therapeutics’ (TSX.V: BCT) (OTCQB: BCTXF) Combination Study with KEYTRUDA® and YERVOY®

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) recently initiated patient dosing in a combination study of lead clinical candidate Bria-IMT with Merck’s (NYSE: MRK) KEYTRUDA® and Bristol-Myers’ (NYSE: BMY) YERVOY®. A recent proof of concept study of Bria-IMT indicated excellent targeted anti-tumor activity and outstanding safety and tolerability in advanced breast cancer patients. An article further discussing the company reads, “BriaCell continues its commitment to exploring new methods of addressing the advanced breast cancer community’s unmet medical needs, and the company is eager to test this novel combination treatment approach and believes that it will offer significant clinical benefits to…

ThursdayOct 18, 2018 10:22 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Lead Clinical Candidate Development Advances Following Promising Phase IIa Results

Clinical-stage biotechnology company BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF) has achieved proof of concept and recently reported promising results from its Phase IIa study of its lead clinical candidate, Bria-IMT. An article further discussing the company reads, “A total of 31 patients with advanced stage breast cancer were enrolled in the Phase II Bria-IMT monotherapy study. The proof of concept and mechanism of action work is based on the results observed in the first 20 patients, while assessment of the remaining 11 patients is still in progress. …The preliminary data seems to confirm the company’s HLA Matching Hypothesis and support…

WednesdayOct 17, 2018 12:48 pm

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Accomplishes Multiple Important Milestones in 2018

In 2018, BriaCell obtained topline safety and efficacy clinical data, achieved proof of concept and advanced its clinical program The company initiated patient dosing in a phase I/IIa clinical trial of its breast cancer immunotherapy Bria-IMT in combination with immune checkpoint inhibitors KEYTRUDA or YERVOY BriaCell is also working on the development of a personalized off-the-shelf immunotherapy treatment for advanced breast cancer that will potentially reduce the cost of tailor-made immunotherapy BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, recently announced the completion of several important milestones in 2018. These include obtaining topline safety and efficacy…

Site Search

Company Search

Tag: BriaCell Therapeutics Corp. BCTXF